ReviewJournal of atherosclerosis and thrombosis2023
Pathophysiology and Optimal Treatment of Intracranial Branch Atheromatous Disease.
Review in Journal of atherosclerosis and thrombosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Tirofiban for Branch Atheromatous Disease-Related Stroke: The STRATEGY Randomized Clinical Trial.JAMA neurology · 2026Article
- Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease (BAD)-Related Stroke: A Multicenter Propensity-Matched Cohort Analysis.CNS neuroscience & therapeutics · 2026Article
- Efficacy and Safety of Intravenous Thrombolysis with Tenecteplase in Patients with Wake-Up Branch Atheromatous Disease.Translational stroke research · 2026Article
- Carotid napkin-ring sign plaques are associated with early neurological deterioration in lenticulostriate artery branch atheromatous disease.Frontiers in neurology · 2026Article
- OCTA-Derived Retinal Biomarkers and Infarct Topography Improve Etiologic Classification of Recent Single Subcortical Infarction: A Nomogram Model.CNS neuroscience & therapeutics · 2026Article
- Hemostatic Activation Markers and Early Neurological Deterioration in Branch Atheromatous Disease-Related Stroke.Journal of atherosclerosis and thrombosis · 2025Observational
- Efficacy and Safety of Tenecteplase in the Treatment of Acute Branch Atheromatous Disease: A Retrospective Multicenter Case-Control Study.Neurology and therapy · 2025Article
- The Diagnostic Value of Contrast-Enhanced Vessel Wall MRI for Diagnosing Neuropsychiatric Systemic Lupus Erythematosus.Journal of magnetic resonance imaging : JMRI · 2025Article
- Occupational Therapy in Acute Branch Atheromatous Disease With Frequent Motor Paralysis Fluctuations: A Case Report.Cureus · 2025Article
- High Middle Cerebral Artery Wall Shear Stress in Branch Atheromatous Disease: A Computational Fluid Dynamics Analysis.Journal of atherosclerosis and thrombosis · 2025Observational
- Chessboard stroke attributed to intracranial atherosclerosis.Arquivos de neuro-psiquiatria · 2025Article
- Effectiveness and Limitations of Intravenous rt-PA Therapy in Patients with Mild Cerebral Infarction.Journal of atherosclerosis and thrombosis · 2025Review
- Article
- Early intensive therapy for preventing neurological deterioration in branch atheromatous disease.Therapeutic advances in neurological disorders · 2025Article
- Association of white matter hyperintensity burden and infarct volume in the anterior choroidal artery territory with early neurological progression: a dual-center retrospective study.Frontiers in aging neuroscience · 2025Article
- Enhanced Hypercoagulability Using Clot Waveform Analysis in Patients with Acute Myocardial Infarction and Acute Cerebral Infarction.Journal of clinical medicine · 2024Article
- Redefining Infarction Size for Small-Vessel Occlusion in Acute Ischemic Stroke: A Retrospective Case-Control Study.Neurology international · 2024Article
- A machine learning-based predictive model for predicting early neurological deterioration in lenticulostriate atheromatous disease-related infarction.Frontiers in neuroscience · 2024Article
- Article
- Tirofiban combined with aspirin for branch atheromatous disease: a propensity score-matched study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracranial branch atheromatous disease (BAD) is a pathological condition characterized by the occlusion of a relatively large perforating branch (700-800 µm) near the orifice of a parent artery due to atherosclerotic plaque-based thrombus (microatheroma). BAD is refractory to treatment and follows a course of progressive exacerbation, especially motor paralysis. Uniform treatment for common atherothrombotic cerebral infarction or lacunar infarction does not prevent the progressive exacerbation of BAD, and consequently affects functional prognosis. To date, various combinations of treatments have been investigated and proposed to attenuate the worsening symptoms of BAD. However, no therapy with established efficacy is yet available for BAD. Since it is the most difficult condition to treat in the area of cerebral infarction, the establishment of optimal treatment methods for BAD is keenly awaited. This review presents an overview of the acute treatments available for BAD and discusses the prospects for optimal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.